{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:27:15Z","timestamp":1792074435868,"version":"4.4.0"},"reference-count":58,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Major advances have been made in the treatment of childhood non-Hodgkin lymphoma (NHL). The recognition that different NHL subtypes require different treatment strategies was fundamental to developing successful therapy regimens. Currently established therapy groups are lymphoblastic lymphoma (LBL) of precursor B- or T-cell type, mature B-cell neoplasms (B-NHL), and anaplastic large cell lymphoma (ALCL). Accurate diagnostic classification is crucial for allocating patients to appropriate treatment groups. Therapy protocols designed to treat children with acute lymphoblastic leukemia (ALL) have proven highly efficacious for treating children with LBL and are associated with event-free survival (EFS) rates up to 80%. For children with B-NHL, a strategy of rapidly repeated short, dose-intense courses proved more efficacious, with EFS rates up to 90%. In patients with ALCL, comparable results are achieved with either strategy, although this group has the highest relapse rate. The price of these efficacious treatments is considerable toxicity. On the other hand, the chance to survive after relapse is still dismal due to the almost complete lack of established salvage regimen. Thus, refinement of the balance between treatment burden and individual patient risk for failure is a major future task. A variety of new treatment options, some already established for treating adult NHL, await evaluation in childhood NHL.<\/jats:p>","DOI":"10.1182\/asheducation-2007.1.285","type":"journal-article","created":{"date-parts":[[2007,11,16]],"date-time":"2007-11-16T18:08:40Z","timestamp":1195236520000},"page":"285-296","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":34,"title":["Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma"],"prefix":"10.1182","volume":"2007","author":[{"given":"Alfred","family":"Reiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019112006394476900_R1","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoetic and Lymphoid Tissues. International Agency for Research on Cancer (IARC) Press: Lyon, France; 2001."},{"key":"2019112006394476900_R2","doi-asserted-by":"crossref","unstructured":"Salzburg J, Burkhardt B, Zimmermann M, et al. Prevalence, clinical pattern, and outcome of CNS-involvement in childhood and adolescent non-Hodgkin lymphoma differ according to NHL subtype\u2014a BFM group report. J Clin Oncol. 2007;25:3815\u20133922.","DOI":"10.1200\/JCO.2007.11.0700"},{"key":"2019112006394476900_R3","doi-asserted-by":"crossref","unstructured":"Anderson JR, Jenkin RD, Wilson JF, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin\u2019s lymphoma: a report of CCG\u2013551 from the Childrens Cancer Group. J Clin Oncol. 1993;11:1024\u20131032.","DOI":"10.1200\/JCO.1993.11.6.1024"},{"key":"2019112006394476900_R4","doi-asserted-by":"crossref","unstructured":"Link MP, Shuster JJ, Donaldson SS, Berard CW, Murphy SB. Treatment of children and young adults with early-stage non-Hodgkin\u2019s lymphoma. N Engl J Med. 1997;337:1259\u20131266.","DOI":"10.1056\/NEJM199710303371802"},{"key":"2019112006394476900_R5","unstructured":"Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95:416\u2013421."},{"key":"2019112006394476900_R6","doi-asserted-by":"crossref","unstructured":"Tubergen DG, Krailo MD, Meadows AT, et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin\u2019s lymphoma: a Childrens Cancer Group study. J. Clin Oncol. 1995;13:1368\u20131376.","DOI":"10.1200\/JCO.1995.13.6.1368"},{"key":"2019112006394476900_R7","doi-asserted-by":"crossref","unstructured":"Patte C, Auperin A, Michon J, et al. The Societe Francaise d\u2019Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97:3370\u20133379.","DOI":"10.1182\/blood.V97.11.3370"},{"key":"2019112006394476900_R8","unstructured":"Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999;94:3294\u20133306."},{"key":"2019112006394476900_R9","doi-asserted-by":"crossref","unstructured":"Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol. 1996;14:1252\u20131261.","DOI":"10.1200\/JCO.1996.14.4.1252"},{"key":"2019112006394476900_R10","doi-asserted-by":"crossref","unstructured":"Cairo MS, Krailo MD, Morse M , et al. Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate (\u2018Orange\u2019) in children with advanced non-lymphoblastic non-Hodgkin\u2019s lymphoma: a children\u2019s cancer group report. Leukemia. 2002;16:594\u2013600.","DOI":"10.1038\/sj.leu.2402402"},{"key":"2019112006394476900_R11","doi-asserted-by":"crossref","unstructured":"Williams DM, Hobson R, Imeson J, et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children\u2019s Cancer Study Group chemotherapy regimens. Br J Haematol. 2002;117:812\u2013820.","DOI":"10.1046\/j.1365-2141.2002.03482.x"},{"key":"2019112006394476900_R12","doi-asserted-by":"crossref","unstructured":"Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 2001;97:3699\u20133706.","DOI":"10.1182\/blood.V97.12.3699"},{"key":"2019112006394476900_R13","doi-asserted-by":"crossref","unstructured":"Rosolen A, Pillon M, Garaventa A, et al. Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer. 2005;104:2133\u20132140.","DOI":"10.1002\/cncr.21438"},{"key":"2019112006394476900_R14","unstructured":"Brugieres L, Deley MC, Pacquement H, et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92:3591\u20133598."},{"key":"2019112006394476900_R15","doi-asserted-by":"crossref","unstructured":"Brugieres L, Quartier P, Le Deley MC, et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children\u2014a report from the French Society of Pediatric Oncology. Ann Oncol. 2000;11:53\u201358.","DOI":"10.1023\/A:1008352726155"},{"key":"2019112006394476900_R16","doi-asserted-by":"crossref","unstructured":"Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B cells. Blood. 1995;86:45\u201353.","DOI":"10.1182\/blood.V86.1.45.bloodjournal86145"},{"key":"2019112006394476900_R17","doi-asserted-by":"crossref","unstructured":"Siebert R, Matthiesen P, Harder S, et al. Application of interphase fluorescence in situ Hybridization for the detection of the Burkitt translocation t(8;14)(q24;q32) in B-cell lymphomas. Blood. 1998;91:984\u2013990.","DOI":"10.1182\/blood.V91.3.984.984_984_990"},{"key":"2019112006394476900_R18","doi-asserted-by":"crossref","unstructured":"van Krieken JH, Langerak AW, Macintyre EA, et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98\u20133936. Leukemia. 2007;21:201\u2013206.","DOI":"10.1038\/sj.leu.2404467"},{"key":"2019112006394476900_R19","doi-asserted-by":"crossref","unstructured":"Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt\u2019s lymphoma. N Engl J Med. 2006;354:2431\u20132442.","DOI":"10.1056\/NEJMoa055759"},{"key":"2019112006394476900_R20","doi-asserted-by":"crossref","unstructured":"Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt\u2019s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419\u20132430.","DOI":"10.1056\/NEJMoa055351"},{"key":"2019112006394476900_R21","doi-asserted-by":"crossref","unstructured":"Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13:335\u2013342.","DOI":"10.1038\/sj.leu.2401310"},{"key":"2019112006394476900_R22","unstructured":"Bergeron C, Celine S, Pacquement H, et al. Childhood T-cell lymphoblastic lymphoma (TLL) Results of the SFOP LMT96 strategy. Pediatr Blood Cancer. 2006;46:967."},{"key":"2019112006394476900_R23","doi-asserted-by":"crossref","unstructured":"Burkhardt B, Woessmann W, Zimmermann M, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006;24:491\u2013499.","DOI":"10.1200\/JCO.2005.02.2707"},{"key":"2019112006394476900_R24","doi-asserted-by":"crossref","unstructured":"Millot F, Suciu S, Philippe N, et al. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol. 2001;19:1935\u20131942.","DOI":"10.1200\/JCO.2001.19.7.1935"},{"key":"2019112006394476900_R25","doi-asserted-by":"crossref","unstructured":"Murphy SB, Bowman WP, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt\u2019s lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol. 1986;4:1732\u20131739.","DOI":"10.1200\/JCO.1986.4.12.1732"},{"key":"2019112006394476900_R26","doi-asserted-by":"crossref","unstructured":"Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105:948\u2013958.","DOI":"10.1182\/blood-2004-03-0973"},{"key":"2019112006394476900_R27","doi-asserted-by":"crossref","unstructured":"Gentet JC, Patte C, Quintana E, et al. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin\u2019s lymphoma: a study of the French Society of Pediatric Oncology. J Clin Oncol. 1990;8:661\u2013665.","DOI":"10.1200\/JCO.1990.8.4.661"},{"key":"2019112006394476900_R28","unstructured":"Patte C, Laplanche A, Bertozzi AI, et al. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin\u2019s lymphoma: a randomized study of the French Society of Pediatric Oncology. J Clin Oncol. 2002;20:441\u2013448."},{"key":"2019112006394476900_R29","doi-asserted-by":"crossref","unstructured":"Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736\u20132743.","DOI":"10.1182\/blood-2006-07-036665"},{"key":"2019112006394476900_R30","doi-asserted-by":"crossref","unstructured":"Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d\u2019Oncologie Pediatrique LMB89 protocol. Ann Oncol. 2002;13:789\u2013795.","DOI":"10.1093\/annonc\/mdf134"},{"key":"2019112006394476900_R31","unstructured":"Gerrard M, Cairo MS, Weston C, et al. Results of the FAB LMB 96 international study in children and adolescents (C+A) with localised, resected B cell lymphoma (large cell [LCL], Burkitt\u2019s [BL] and Burkitt-like [BLL]). J Clin Oncol. 2003;22:795."},{"key":"2019112006394476900_R32","doi-asserted-by":"crossref","unstructured":"Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773\u20132780.","DOI":"10.1182\/blood-2006-07-036673"},{"key":"2019112006394476900_R33","doi-asserted-by":"crossref","unstructured":"Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005;23:541\u2013547.","DOI":"10.1200\/JCO.2005.11.075"},{"key":"2019112006394476900_R34","doi-asserted-by":"crossref","unstructured":"Brugieres L, Le Deley MC, Rosolen A, et al. Anaplastic large cell lympoma (ALCL) in children: equal efficacy but greater toxicity of chemotherapy including methotrexate (MTX) 1g\/ m2 in 24-hour infusion with intrathecal injection (IT) than chemotherapy with MTX 3g\/m2 in 3-hour infusion without IT: results of the ALCL99\u2013R1 randomized trial [abstract]. Blood. 2006;108:122a.","DOI":"10.1182\/blood.V108.11.398.398"},{"key":"2019112006394476900_R35","doi-asserted-by":"crossref","unstructured":"Seidemann K, Tiemann M, Lauterbach I, et al. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 2003;21:1782\u20131789.","DOI":"10.1200\/JCO.2003.08.151"},{"key":"2019112006394476900_R36","unstructured":"Schmitt C, Delsol G, Brugieres L, et al. Lymphohistiocytic variant of anaplastic large cell lymphoma in children and adolescents: a long-term study by the French society of pediatric cancer--lymphoma group. Pediatr Blood Cancer. 2006;46:841\u2013842."},{"key":"2019112006394476900_R37","doi-asserted-by":"crossref","unstructured":"Onciu M, Schlette E, Zhou Y, et al. Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma. Cancer. 2006;107:1084\u20131092.","DOI":"10.1002\/cncr.22089"},{"key":"2019112006394476900_R38","unstructured":"Poirel HA, Heerema NA, Swansbury J, et al. Cytogenetic analysis of 238 pediatric mature B-cell non-Hodgkin lymphoma (NHL) cases from the randomized international FAB LMB96 trial identities several patterns of chromosomal abnormality and new prognostic factors. Pediatr Blood Cancer. 2006;46:835."},{"key":"2019112006394476900_R39","doi-asserted-by":"crossref","unstructured":"Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376\u20131381.","DOI":"10.1182\/blood-2005-01-0272"},{"key":"2019112006394476900_R40","doi-asserted-by":"crossref","unstructured":"Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101:3875\u20133876.","DOI":"10.1182\/blood-2002-09-2778"},{"key":"2019112006394476900_R41","doi-asserted-by":"crossref","unstructured":"Damm-Welk C, Busch K, Burkhardt B, et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2007;110:670\u2013677.","DOI":"10.1182\/blood-2007-02-066852"},{"key":"2019112006394476900_R42","doi-asserted-by":"crossref","unstructured":"Mussolin L, Basso K, Pillon M, et al. Prospective analysis of minimal bone marrow infiltration in pediatric Burkitt\u2019s lymphomas by long-distance polymerase chain reaction for t(8;14)(q24;q32). Leukemia. 2003;17:585\u2013589.","DOI":"10.1038\/sj.leu.2402828"},{"key":"2019112006394476900_R43","doi-asserted-by":"crossref","unstructured":"Fields KK, Zorsky PE, Hiemenz JW, Kronish LE, Elfenbein GJ. Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity. J Clin Oncol. 1994;12:544\u2013552.","DOI":"10.1200\/JCO.1994.12.3.544"},{"key":"2019112006394476900_R44","doi-asserted-by":"crossref","unstructured":"Kobrinsky NL, Sposto R, Shah NR, et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease with dexamethasone, etoposide, cisplatin, cytarabine, and L-asparaginase, maintenance chemotherapy, and transplantation: Children\u2019s Cancer Group Study CCG-5912. J Clin Oncol. 2001;19:2390\u20132396.","DOI":"10.1200\/JCO.2001.19.9.2390"},{"key":"2019112006394476900_R45","doi-asserted-by":"crossref","unstructured":"Attarbaschi A, Dworzak M, Steiner M, et al. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group. Pediatr Blood Cancer. 2005;44:70\u201376.","DOI":"10.1002\/pbc.20121"},{"key":"2019112006394476900_R46","unstructured":"Burkhardt B, Reiter A, Lang P, et al. Relapse in pediatric pts with T-cell lymphoblastic lymphoma: clinical characteristics and outcome in the BFM group. Pediatr Blood Cancer. 2006;46:842."},{"key":"2019112006394476900_R47","doi-asserted-by":"crossref","unstructured":"Atra A, Gerrard M, Hobson R, et al. Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin\u2019s lymphoma treated with the UKCCSG 9003\/9002 protocols. Br J Haematol. 2001;112:965\u2013968.","DOI":"10.1046\/j.1365-2141.2001.02647.x"},{"key":"2019112006394476900_R48","doi-asserted-by":"crossref","unstructured":"Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents\u2014a Berlin-Frankfurt-Munster group report. Br J Haematol. 2006;133:176\u2013182.","DOI":"10.1111\/j.1365-2141.2006.06004.x"},{"key":"2019112006394476900_R49","doi-asserted-by":"crossref","unstructured":"Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006;107:4207\u20134213.","DOI":"10.1182\/blood-2005-10-4222"},{"key":"2019112006394476900_R50","doi-asserted-by":"crossref","unstructured":"Oschlies I, Klapper W, Zimmermann M, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood. 2006;107:4047\u20134052.","DOI":"10.1182\/blood-2005-10-4213"},{"key":"2019112006394476900_R51","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851\u2013862.","DOI":"10.1084\/jem.20031074"},{"key":"2019112006394476900_R52","doi-asserted-by":"crossref","unstructured":"Lones MA, Heerema NA, Le Beau MM, et al. Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08. Cancer Genet Cytogenet. 2007;172:1\u201311.","DOI":"10.1016\/j.cancergencyto.2006.07.011"},{"key":"2019112006394476900_R53","doi-asserted-by":"crossref","unstructured":"Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131:39\u201349.","DOI":"10.1111\/j.1365-2141.2005.05735.x"},{"key":"2019112006394476900_R54","doi-asserted-by":"crossref","unstructured":"Burkhardt B, Bruch J, Zimmermann M, et al. Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia. 2006;20:1422\u20131429.","DOI":"10.1038\/sj.leu.2404275"},{"key":"2019112006394476900_R55","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002;100:52\u201358.","DOI":"10.1182\/blood-2002-01-0006"},{"key":"2019112006394476900_R56","doi-asserted-by":"crossref","unstructured":"Seidemann K, Zimmermann M, Book M, et al. Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin\u2019s lymphoma: results from Berlin-Frankfurt-Munster Trial NHL-BFM 95. J Clin Oncol. 2005;23:8414\u20138421.","DOI":"10.1200\/JCO.2005.01.2179"},{"key":"2019112006394476900_R57","doi-asserted-by":"crossref","unstructured":"Le Deley MC, Brugieres L, Williams DM, Reiter A. Prognostic factors in childhood anaplastic large cell lymphoma (ALCL): results of the European Intergroup Study [abstract]. Blood. 2006;108:581a.","DOI":"10.1182\/blood.V108.11.2050.2050"},{"key":"2019112006394476900_R58","doi-asserted-by":"crossref","unstructured":"Mussolin L, Pillon M, d\u2019Amore ES, et al. Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma. Leukemia. 2005;19:1643\u20131647.","DOI":"10.1038\/sj.leu.2403888"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/285\/646363\/285_296ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/285\/646363\/285_296ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T06:57:58Z","timestamp":1588057078000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2007\/1\/285\/178067\/Diagnosis-and-Treatment-of-Childhood-NonHodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2007.1.285","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}